The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41  by Xu, Younong et al.
The possible involvement of CXCR4 in the inhibition of HIV-1 infection
mediated by DP178/gp41
Younong Xua, Xiaoyan Zhangb, Masao Matsuokaa, Toshio Hattorib;*
aLaboratory of Virus Immunology, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan
bDivision of Allergy and Infectious Diseases, Department of Internal Medicine, Graduate School of Medicine, Tohoku University, 1-1 Seiryo-cho,
Aoba-ku, Sendai 980-8574, Japan
Received 4 September 2000; revised 20 November 2000; accepted 27 November 2000
First published online 5 December 2000
Edited by Hans-Dieter Klenk
Abstract The N- (N36/DP107) and C-terminal peptides (C34/
DP178) from two K-helical domains of human immunodeficiency
virus type 1 (HIV-1) gp41 inhibited HIV infection. A single-
round infection using pseudotyped virus clarified that a greater
amount of gp41-derived peptides was necessary for the inhibition
of R5 virus (ADA) infection than for that of X4 virus (LAI)
infection. Furthermore, R5X4 virus (89.6) infection via CCR5
needs more peptides for inhibition than its infection via CXCR4
does. A high sensitivity of X4 virus was partially ascribed
to the inhibition of the 12G5 binding to CXCR4 by
DP178LAI. ß 2000 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The gp120 human immunode¢ciency virus type 1 (HIV-1)
binds to CD4 receptor as well as to chemokine receptors on
target cells [1^3]. Then gp41 undergoes a conformational
change that promotes viral and cellular membrane fusion.
These conformational changes are thought to be involved in
the transition of gp41 from a native (non-fusogenic) to a
fusion-active (fusogenic) state.
The ectodomain of the gp41 molecule is directly involved in
the membrane fusion process. Recent crystallographic studies
on the core of fusion-active gp41 using N36 and C34 peptides
showed that they fold into a six-helix bundle, in which three
N-terminal helices form an interior, parallel-coiled-coil trimer,
while three C-terminal helices pack in the reverse direction
into three hydrophobic grooves on the surface of this
coiled-coil [4,5]. A number of reports favor the notion that
this six-helix structure represents the fusion-active conforma-
tion of the gp41 ectodomain core [6,7]. The synthetic peptides
with these heptad repeats (N-terminal peptides: N36, DP107;
C-terminal peptides: C34, DP178) could inhibit HIV infection
and have been proposed to work in a dominant-negative man-
ner [8,9]. Here we found that the R5 or R5X4 virus using
CCR5 for entry is more resistant to the inhibition by these
gp41-derived peptides than X4 or R5X4 virus using CXCR4
and studied its mechanism.
2. Materials and methods
2.1. Peptide synthesis
T22 derived from polyphemusin II in American horseshoe crab was
synthesized as previously described [10]. DP107, DP178, C34, and
N36 derived from gp41 of the envelope glycoprotein of the HIV-1
LAI strain and DP178 from the ADA strain were synthesized (Fig.
1) as described [4,9].
2.1. Cell culture
All cells were cultured in 100% humidi¢ed air at 37‡C with 5% CO2.
A human embryonic kidney cell line, 293T, and human astroglia cell
lines (U87) expressing CD4 antigen and the co-receptors CXCR4
(U87.CD4.CXCR4) or CCR5 (U87.CD4.CCR5) were provided by
Dr. D. Littman [2]. The CEM-CCR5 (provided by Dr. Maeda, Ku-
mamoto University) and Sup-T1 cells were used for the analysis of co-
receptor expression. The establishment of CEM-CCR5 was similar to
that of Molt-4#8/CCR5 by Dr. Maeda [11]. The peripheral blood
mononuclear cells (PBMCs) were isolated from the bu¡y-coat, cul-
tured with 5 Wg/ml phytohemagglutinin (PHA, Difco, Detroit, MI,
USA) for 2 days before they are used for HIV infection or £ow-cy-
tometry as described [12].
2.2. Vectors and luciferase assay
The P. pyralis luciferase expression vector pNL4-3-Luc-E3R3, and
the envelope genes of a X4 virus (LAI), R5 virus (ADA), and R5X4
virus (89.6) were co-transfected into 293T cells to produce pseudo-
typed viruses. The pseudotyped viruses were quanti¢ed by a p24 en-
zyme-linked immunosorbent assay (ABBOTT, Abbott Park, IL,
USA), and were used for infection of U87.CD4.CXCR4 or CCR5
cells as described [2,10].
2.3. Preparation of virus stocks and inhibition assay
Virus stocks of HIV-1 SF162 (provided by Dr. Koito, Kumamoto
University), HIV-1 ADA (provided from NIH AIDS Research and
Reference Reagent Program) and pNL432 (provided from Dr. A.
Adachi) [13] were prepared and infected as described [12].
Virus titration and inhibition assays were done in PBMCs as pre-
viously described [14]. The 50% inhibition concentration (IC50) of the
peptides was calculated to show a 50% reduction of viral p24 antigen
expression in the presence of the peptide compared to the positive
control.
2.4. Monoclonal antibodies and £ow-cytometry
12G5, a monoclonal antibody to CXCR4, was kindly provided by
Dr. J.A. Hoxie and 2D7 (anti-CCR5) by LeukoSite, Inc. through the
NIH AIDS Research and Reference Reagent Program [15]. Leu3a
(anti-CD4) was purchased from Becton Dickinson and Co. (San
Jose, CA, USA). Fluorescein-isothiocyanate-conjugated goat F(abP)2
anti-mouse immunoglobulin G (Biosource, Menlo Park, CA, USA)
was used as second antibody. Surface molecules on reagent-treated
Sup-T1 cells or 48 h PHA-stimulated PBMCs were quantitated by a
FACScan (Becton Dickinson and Co., Mountain View, CA, USA)
using Consort 30 software as described [10].
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3. Results
3.1. Higher amounts of gp41-derived peptides were necessary
for inhibition of R5 virus infection than for that of X4 virus
infection
To determine whether the infection of HIV with di¡erent
tropism was in£uenced by these gp41-derived peptides
(DP107LAI, DP178ADA, DP178LAI, N36LAI and
C34LAI), the e¡ects of these peptides on the entry of two
pseudotyped viruses with di¡erent tropism (X4 pseudotyped
virus LAI, R5 pseudotyped virus ADA) were analyzed.
U87.CD4.CXCR4 or CCR5 were used as target cells. All
gp41-derived peptides inhibited the infection of both the X4
and R5 virus in a dose-dependent manner(data no shown). As
shown in Fig. 2, the values of IC50s of all peptides that in-
hibited the ADA infection of U87.CD4.CCR5 cells were at
least 2-fold higher than those of the peptides that inhibited the
LAI infection of U87.CD4.CXCR4 cells. The IC50 ratios be-
tween the inhibition of ADA infection and that of LAI in-
fection by peptides were 3.3 for DP107LAI, 12 for N36LAI,
15 for DP178ADA, 221 for DP178LAI, 2082 for C34LAI,
respectively. These results indicate that the R5 virus (pseudo-
typed virus ADA) is more resistant to the inhibition by both
N- and C-peptides than is the X4 virus (pseudotyped virus
LAI). Especially, the R5 virus showed much more resistance
than the X4 virus to inhibition when the C-peptides
(DP178LAI or C34LAI) were used.
It is possible that the high sensitivity of X4 virus to the
peptides could be ascribed to the unique feature of U87 cells
or pseudotyped viruses. The e¡ects of these peptides were also
investigated using PBMCs infected with replicating viruses
(pNL43, SF162, and ADA) (Fig. 3). We also found that the
R5 virus (SF162 and ADA) is more resistant to the inhibition
by both N- and C-peptides than is the X4 virus (pNL43).
3.2. The expression of CXCR4 or CCR5 on target cells
The expression of CXCR4 or CCR5 on U87 cell lines and
48 h PHA-stimulated PBMCs was relatively compared using
12G5 (anti-CXCR4) and 2D7 (anti-CCR5) monoclonal anti-
bodies. The mean £uorescence intensities (MFI) were 13.43
for 12G5 on U87.CD4.CXCR4 and 16.55 for 2D7 on
U87.CD4.CCR5, respectively, indicating that the expression
levels of CXCR4 and CCR5 on U87 cells are relatively close.
The MFI are 159.80 for CXCR4 and 41.38 for CCR5 on
PBMCs, respectively, indicating the PBMC expressed a great-
er amount of CXCR4 than CCR5 following the IL-2 stimu-
lation. Also the expression levels of CD4 on both
U87.CD4.CXCR4 and U87.CD4.CCR5 are very close, 76.5
and 73.7 of MFI, respectively.
Therefore, it is less likely that the expression levels of
CXCR4 or CCR5 account for the di¡erent sensitivities to
the peptides.
3.3. The R5X4 virus also needs more peptides for its resistance
to CCR5-mediated infection
To determine whether the infection of dual tropic virus was
blocked by these gp41-derived peptides, the e¡ects of the pep-
tides on the entry of dual tropic pseudotyped viruses (R5X4
pseudotyped virus 89.6) into U87.CD4.CXCR4 or CCR5
were studied. It should also be noted that luciferase activities
of CXCR4 expressing cells were greater than those of CCR5
Fig. 1. Sequences of gp41-derived peptides (N-terminal peptides:
DP107LAI, N36LAI; C-terminal peptides: DP178LAI, DP178ADA
and C34LAI). These peptides are aligned on the basis of their ho-
mology. The dashed line indicates the homology of N36LAI to
DP107LAI, or DP178ADA, C34LAI to DP178LAI.
Fig. 2. E¡ects of gp41-derived peptides on the entry of X4 and R5
pseudotyped viruses. Results are expressed as the means þ S.D. and
are representative of three separate experiments. IC50 (WM) values
are based on the 50% reduction of pseudotyped virus LAI or ADA-
induced luciferase activity in U87.CD4.CXCR4 or U87.CD4.CCR5
cells. **P6 0.01.
Fig. 3. E¡ects of gp41-derived peptides on the infection of X4
(pNL432) and R5 viruses (ADA and SF162) in PBMCs. Results are
expressed as the means þ S.D. and are representative of three sepa-
rate experiments. p24 (ng/ml) is 91.5 þ 2.2 for pNL432, 79.1 þ 1.1
for ADA, 77.1 þ 3.1 for SF162 in the absence of peptides. IC50
(WM) values are based on the 50% reduction of viral p24 expression
in PHA-stimulated PBMCs. **P6 0.01; *P6 0.05.
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cells. The di¡erent IC50s of the two infections could be ex-
plained by di¡erences in the e⁄ciencies of infection by the
di¡erent co-receptor expressing cells. However, the IC50 ratios
of the infection for U87.CD4.CCR5 and that for
U87.CD4.CXCR4 by peptides were variable; 2.0 for
DP107LAI, 6.5 for N36LAI, 3.0 for DP178ADA, 33 for
DP178LAI, and 3.9 for C34LAI, respectively, indicating
that more peptides are needed to inhibit R5X4 infection medi-
ated via CCR5 compared to its infection mediated via
CXCR4 (Fig. 4). These results suggested that the e⁄cient
infection of the R5X4 virus (pseudotyped virus 89.6) could
partly explain the R5 resistance, but the markedly high ratio
for DP178LAI must be explained by a di¡erent mechanism.
3.4. DP178LAI inhibits X4 or R5X4 virus infection also
through interaction with CXCR4
To clarify the reason for the greater resistance of the R5 or
R5X4 virus using CCR5 to inhibition by gp41-derived pep-
tides, we investigated whether the peptides could interact with
cell surfaces on target cells. We examined the e¡ect of
C34LAI and DP178LAI on the binding of an anti-CXCR4
monoclonal antibody (12G5) to CXCR4, and an anti-CCR5
monoclonal antibody (2D7) to CCR5 using £ow-cytometry.
We found that the incubation of Sup-T1 cells with 10 WM T22
completely inhibited the binding of 12G5 to CXCR4, and
incubation of Sup-T1 with 10 WM DP178LAI also inhibited
the binding of 12G5 to CXCR4 in a dose-dependent manner,
while C34LAI had no e¡ect on the binding of 12G5 (Fig. 5).
Other peptides did not show any inhibitory activities. The
incubation of CEM-CCR5 with 10 WM of all gp41-derived
peptides (DP178LAI, DP107LAI, DP178ADA, N36LAI,
and C34LAI) had no e¡ect on the binding of 2D7 to CCR5
(data not shown). These results indicate that DP178LAI in-
hibits X4 or R5X4 virus infection also through interaction
with CXCR4.
4. Discussion
It was recently clari¢ed that a series of monoclonal anti-
bodies derived from patients including 98.6 and 50-69 could
recognize fusogenic forms or trimeric forms of gp41 [16^18].
These data indicated the existence of fusogenic forms of gp41
in vivo and the importance of oligomeric forms of gp41 for
development of humoral immune response. To further under-
stand the functional role of the putative coiled-coil sequence
in ectodomain of gp41 which could arouse conformational
antibodies, the N- (N36LAI, DP107LAI), and C-terminal
peptides (C34LAI, DP178LAI, and DP178ADA) were synthe-
sized. We found that the R5 virus (pseudotyped virus ADA) is
more resistant to the inhibition by both N- and C-peptides
than is the X4 virus (pseudotyped virus LAI). The resistance
could not be explained by sequence variability, because the
IC50 of DP178ADA against LAI was lower than that against
ADA. The R5X4 virus (pseudotyped virus 89.6) was more
resistant to inhibition by N-peptide (N36) and C-peptides
(DP178 or C34) when it used CCR5 as co-receptor for entry
(Fig. 4). In this case, the pseudotyped virus 89.6 could infect
U87.CD4 cells more e⁄ciently via CXCR4 than via CCR5,
and di¡erences in the IC50 between both infections may be
explained by the e⁄ciencies of infection by the di¡erent co-
receptor expressing cells. However a greater amount of pep-
tides was always necessary for the R5 virus, especially when
C-terminal peptides were used.
Recently, DP178 has been reported to be the activator of
the human phagocyte N-formyl peptide receptor and to bind
to the putative cellular receptor protein P62 [19]. Here, we
also found that DP178LAI could partially inhibit the binding
of CXCR4 on Sup-T1 by 12G5. This may additively in£uence
the sensitivity of X4 virus to inhibition by DP178LAI.
Although there is much evidence indicating that gp41-derived
peptides exert their inhibitory e¡ect by interfering with the
Fig. 5. gp41-derived peptides act as potent inhibitors of chemoat-
tractant receptors. The MFI for 12G5 alone is 206 þ 8. Dose-depen-
dent e¡ect of DP178LAI, C34LAI and T22 on the binding of
CXCR4 on Sup-T1 cells by 12G5.
Fig. 4. E¡ects of gp41-derived peptides on the entry of R5X4 pseu-
dotyped viruses (89.6) into U87.CD4.CXCR4 or U87.CD4.CCR5
cells. The luciferase activity (mv) in the absence of peptide is
673 468.8 þ 30 247 for infection of U87.CD4.CXCR4 and
47 484.35 þ 4128 for infection of U87.CD4.CCR5. Results are ex-
pressed as the means þ S.D. and are representative of three separate
experiments. IC50 (WM) values are based on the 50% reduction of
pseudotyped virus 89.6-induced luciferase activity in
U87.CD4.CXCR4 or U87.CD4.CCR5 cells. **P6 0.01; *P6 0.05;
#, over 20.
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formation of gp41 trimer, our data suggest that DP178LAI
may also exert its e¡ect by binding to CXCR4 or hindering
the binding of X4 gp120 to CXCR4.
It is not immediately clear why di¡erent co-receptor usage
would in£uence susceptibility of a viral isolate to inhibition by
gp41-derived peptides. One possible explanation for the resis-
tance of CCR5-using virus to inhibition by gp41-derived pep-
tides is that gp120 binding to CD4 and CCR5 induces con-
formational changes that hinder the peptide interactions with
its counterpart helical domain, while gp120 binding to CD4
and CXCR4 induces a conformation more conducive to the
peptide association with its counterpart [6,7,20,21]. Thus, the
higher resistance of R5 or X4R5 viruses using CCR5 to gp41-
derived peptides’ inhibition could be explained by less e⁄cient
dissociation of gp120 from gp41 upon interaction with CD4
and CCR5 than with CD4 and CXCR4.
Another possibility is that speci¢c inhibition of X4 virus by
tat also partially explains the more sensitivity of X4 virus than
R5 virus to inhibition [22].
Furthermore, the resistance of primary viruses against
broadly neutralizing monoclonal antibodies has been reported
[23]. Our ¢ndings here suggested that this resistance of pri-
mary isolates could also be observed in gp41-derived peptides,
though the mechanisms is not well understood. It should also
be examined whether such resistance could also be observed in
vivo, because the therapeutic e⁄cacy of these peptides has
also been claimed [24].
Note: after submission of this work, we noted that similar
¢ndings were reported by Derdeyn et al. [25].
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